EMA Authorised: Efient (prasugrel) — Substipharm

View source ↗

Summary

The EMA has authorised Efient (prasugrel) by Substipharm for indications including acute coronary syndrome, unstable angina, and myocardial infarction.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Syndrome
• Myocardial Infarction
• Unstable Angina

Drugs mentioned

• Efient (prasugrel)

Snippet

Status: Authorised. Therapeutic area: Acute Coronary Syndrome;Angina, Unstable;Myocardial Infarction. MAH: Substipharm. Decision date: 22/07/2025